标题
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 17, Issue 3, Pages 197-223
出版商
Springer Nature
发表日期
2017-12-01
DOI
10.1038/nrd.2017.227
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Screening-based approaches to identify small molecules that inhibit protein–protein interactions
- (2017) Sehee Choi et al. Expert Opinion on Drug Discovery
- PEGylation prolongs the pulmonary retention of an anti-IL-17A Fab’ antibody fragment after pulmonary delivery in three different species
- (2017) Danielle Freches et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells
- (2017) Annalina Tammen et al. JOURNAL OF IMMUNOLOGY
- The making of bispecific antibodies
- (2017) Ulrich Brinkmann et al. mAbs
- Chaperone proteins as single component reagents to assess antibody nonspecificity
- (2017) Ryan L. Kelly et al. mAbs
- Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
- (2017) Miroslav Dostalek et al. mAbs
- Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
- (2017) Julian Andreev et al. MOLECULAR CANCER THERAPEUTICS
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
- (2017) Elie Dheilly et al. MOLECULAR THERAPY
- Stop Alzheimer’s before it starts
- (2017) Eric McDade et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Industry 'road tests' new wave of immune checkpoints
- (2017) Ken Garber NATURE BIOTECHNOLOGY
- Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
- (2017) Catherine J. Hutchings et al. NATURE REVIEWS DRUG DISCOVERY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody therapies in CNS diseases
- (2017) Per-Ola Freskgård et al. NEUROPHARMACOLOGY
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antidrug Antibodies in Patients Treated with Alirocumab
- (2017) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanobodies® † †Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases
- (2017) Gino Van Heeke et al. PHARMACOLOGY & THERAPEUTICS
- Biophysical properties of the clinical-stage antibody landscape
- (2017) Tushar Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacokinetic aspects of retinal drug delivery
- (2017) Eva M. del Amo et al. PROGRESS IN RETINAL AND EYE RESEARCH
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Long-acting protein drugs for the treatment of ocular diseases
- (2017) Joy G. Ghosh et al. Nature Communications
- Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
- (2017) Seung-Min Shin et al. Nature Communications
- Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
- (2017) Yariv Mazor et al. Scientific Reports
- A quantitative comparison of cytosolic delivery via different protein uptake systems
- (2017) Wouter P. R. Verdurmen et al. Scientific Reports
- Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases
- (2017) Taku Fukuzawa et al. Scientific Reports
- Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
- (2016) Elena Moroz et al. ADVANCED DRUG DELIVERY REVIEWS
- Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates
- (2016) Matthew R. Levengood et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
- (2016) Ira Jacobs et al. BIODRUGS
- Assessing the Immunogenicity of Biopharmaceuticals
- (2016) Carlos Pineda et al. BIODRUGS
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2016) John Y. Li et al. CANCER CELL
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
- (2016) Eugene A Zhukovsky et al. CURRENT OPINION IN IMMUNOLOGY
- Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease
- (2016) Davide Corti et al. CURRENT OPINION IN IMMUNOLOGY
- Immunocytokines for cancer treatment: past, present and future
- (2016) Dario Neri et al. CURRENT OPINION IN IMMUNOLOGY
- Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?
- (2016) Janine Schuurman et al. CURRENT OPINION IN IMMUNOLOGY
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
- (2016) Franziska Bootz et al. DRUG DISCOVERY TODAY
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies
- (2016) William M. Pardridge EXPERT OPINION ON BIOLOGICAL THERAPY
- Opportunities and challenges for TCR mimic antibodies in cancer therapy
- (2016) Aaron Y. Chang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches
- (2016) Vibhuti Agrahari et al. Expert Opinion on Drug Delivery
- CSF, blood-brain barrier, and brain drug delivery
- (2016) William M. Pardridge Expert Opinion on Drug Delivery
- Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
- (2016) Di Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
- (2016) M. Scott Harris et al. Journal of Crohns & Colitis
- Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
- (2016) Erika M. Cook et al. JOURNAL OF IMMUNOLOGY
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
- (2016) Songmao Zheng et al. mAbs
- Target-independent variable region mediated effects on antibody clearance can be FcRn independent
- (2016) Ryan L. Kelly et al. mAbs
- Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys
- (2016) Amita Datta-Mannan et al. mAbs
- The use of CrossMAb technology for the generation of bi- and multispecific antibodies
- (2016) Christian Klein et al. mAbs
- Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63
- (2016) B. E. C. G. de Goeij et al. MOLECULAR CANCER THERAPEUTICS
- Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab
- (2016) Whitney Shatz et al. MOLECULAR PHARMACEUTICS
- Failed Alzheimer’s trial does not kill leading theory of disease
- (2016) Alison Abbott et al. NATURE
- In vitro and ex vivo strategies for intracellular delivery
- (2016) Martin P. Stewart et al. NATURE
- The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
- (2016) Jeff Sevigny et al. NATURE
- A comprehensive map of molecular drug targets
- (2016) Rita Santos et al. NATURE REVIEWS DRUG DISCOVERY
- Ten years of anti-vascular endothelial growth factor therapy
- (2016) Napoleone Ferrara et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies
- (2016) Y. Joy Yu Zuchero et al. NEURON
- A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses
- (2016) Anna Z. Wec et al. SCIENCE
- MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
- (2016) Sabrina Arena et al. Science Translational Medicine
- Coming-of-Age of Antibodies in Cancer Therapeutics
- (2016) B. Vijayalakshmi Ayyar et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?—An Overview
- (2016) Louis P. Garrison VALUE IN HEALTH
- Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins
- (2016) Alison Smith et al. Journal of Immunology Research
- Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection
- (2015) Laurent Detalle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
- (2015) Takuya Osada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
- (2015) A. V. Yurkovetskiy et al. CANCER RESEARCH
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Principles of antibody-mediated TNF receptor activation
- (2015) H Wajant CELL DEATH AND DIFFERENTIATION
- Antibody therapies and their challenges in the treatment of age-related macular degeneration
- (2015) Cornelia Volz et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Oligoclonal antibodies to target the ErbB family
- (2015) Jimson W D’Souza et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
- (2015) Jose M. M. Caaveiro et al. IMMUNOLOGICAL REVIEWS
- Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics
- (2015) Daniela Bumbaca Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions
- (2015) Avi Ashkenazi JOURNAL OF CLINICAL INVESTIGATION
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems
- (2015) Wouter P.R. Verdurmen et al. JOURNAL OF CONTROLLED RELEASE
- The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology
- (2015) Rinpei Niwa et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Developability Assessment During the Selection of Novel Therapeutic Antibodies
- (2015) Alexander Jarasch et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- An Immunosuppressive Antibody–Drug Conjugate
- (2015) Rongsheng E. Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
- (2015) Karin A van Schie et al. mAbs
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- Improving target cell specificity using a novel monovalent bispecific IgG design
- (2015) Yariv Mazor et al. mAbs
- Insights into the molecular basis of a bispecific antibody's target selectivity
- (2015) Yariv Mazor et al. mAbs
- A novel screening method to assess developability of antibody-like molecules
- (2015) Neeraj Kohli et al. mAbs
- A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
- (2015) Emily C Piccione et al. mAbs
- The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies
- (2015) Amita Datta-Mannan et al. mAbs
- Aggregation risk prediction for antibodies and its application to biotherapeutic development
- (2015) Olga Obrezanova et al. mAbs
- Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
- (2015) Amita Datta-Mannan et al. mAbs
- A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
- (2015) Colby A Souders et al. mAbs
- Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
- (2015) J. D. Kearns et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of action of therapeutic antibodies for cancer
- (2015) J.M. Redman et al. MOLECULAR IMMUNOLOGY
- Targeting FcRn for the modulation of antibody dynamics
- (2015) E. Sally Ward et al. MOLECULAR IMMUNOLOGY
- ImmTACs for targeted cancer therapy: Why, what, how, and which
- (2015) Joanne Oates et al. MOLECULAR IMMUNOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue
- (2015) Susan Hua et al. Nanomedicine-Nanotechnology Biology and Medicine
- Novel antibody–antibiotic conjugate eliminates intracellular S. aureus
- (2015) Sophie M. Lehar et al. NATURE
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Monoclonal antibody biosimilars
- (2015) Natasha Udpa et al. NATURE REVIEWS DRUG DISCOVERY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans
- (2015) Victoria S Jasion et al. Nutrition Journal
- Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
- (2015) Angela Schoch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy
- (2015) Jiemin Wu et al. PROTEIN ENGINEERING DESIGN & SELECTION
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates
- (2015) Gurunadh R. Chichili et al. Science Translational Medicine
- Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
- (2015) R. Dienstmann et al. Cancer Discovery
- TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2
- (2015) Taro Tamada et al. Scientific Reports
- A review of blinatumomab, a novel immunotherapy
- (2015) Matthew J Newman et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
- (2015) Ganesh Kolumam et al. EBioMedicine
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- Safety and Pharmacokinetics of XOMA 3AB, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin A
- (2014) S. U. Nayak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- pH-dependent antigen-binding antibodies as a novel therapeutic modality
- (2014) T. Igawa et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
- (2014) J. A. Woyach et al. BLOOD
- Delivery of Antibody Mimics into Mammalian Cells via Anthrax Toxin Protective Antigen
- (2014) Xiaoli Liao et al. CHEMBIOCHEM
- LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth
- (2014) L. Liu et al. CLINICAL CANCER RESEARCH
- pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
- (2014) M. Jack Borrok et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ocular delivery of macromolecules
- (2014) Yoo Chun Kim et al. JOURNAL OF CONTROLLED RELEASE
- PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract
- (2014) Salome Juliette Koussoroplis et al. JOURNAL OF CONTROLLED RELEASE
- Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system
- (2014) L. Guilleminault et al. JOURNAL OF CONTROLLED RELEASE
- Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
- (2014) Ann L. White et al. JOURNAL OF IMMUNOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Non–antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity
- (2014) Zenjiro Sampei et al. mAbs
- Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics
- (2014) Gwendolyn M Wilmes et al. mAbs
- VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations
- (2014) Virginie Hervé et al. mAbs
- Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches
- (2014) Paul Casaz et al. mAbs
- Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19
- (2014) Dániel Szili et al. mAbs
- A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells
- (2014) Dong-Ki Choi et al. mAbs
- Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection
- (2014) Alexandra Lavoisier et al. mAbs
- Highly Viscous Antibody Solutions Are a Consequence of Network Formation Caused by Domain–Domain Electrostatic Complementarities: Insights from Coarse-Grained Simulations
- (2014) Patrick M. Buck et al. MOLECULAR PHARMACEUTICS
- A draft map of the human proteome
- (2014) Min-Sik Kim et al. NATURE
- Biopharmaceutical benchmarks 2014
- (2014) Gary Walsh NATURE BIOTECHNOLOGY
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
- (2014) Jens Niewoehner et al. NEURON
- Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
- (2014) Stephen Salloway et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
- (2014) Y. J. Yu et al. Science Translational Medicine
- The global prevalence of dementia: A systematic review and metaanalysis
- (2013) Martin Prince et al. Alzheimers & Dementia
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
- (2013) Gabriel J. Robbie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
- (2013) Gregory Gaich et al. Cell Metabolism
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
- (2013) Timo Rath et al. CRITICAL REVIEWS IN BIOTECHNOLOGY
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass – Prediction of viscosity through protein–protein interaction measurements
- (2013) Martin S. Neergaard et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey
- (2013) Chee M. Ng et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations
- (2013) Xiaotong Wang et al. Genome Biology and Evolution
- AVX-470
- (2013) Kailash C. Bhol et al. INFLAMMATORY BOWEL DISEASES
- Inhaled proteins: Challenges and perspectives
- (2013) Flore Depreter et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
- (2013) Zhi Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
- (2013) Jeong M. Kim et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63-Polyubiquitin-Dependent Signals from Endosomes
- (2013) I. Martinez-Forero et al. JOURNAL OF IMMUNOLOGY
- The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
- (2013) C Kellner et al. LEUKEMIA
- Developability studies before initiation of process development
- (2013) Xiaoyu Yang et al. mAbs
- Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
- (2013) Futa Mimoto et al. mAbs
- Antibody biodistribution coefficients
- (2013) Dhaval K. Shah et al. mAbs
- Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
- (2013) Josée Golay et al. mAbs
- Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies
- (2013) Gabriele Proetzel et al. METHODS
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
- (2013) Zenjiro Sampei et al. PLoS One
- Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
- (2013) Ai-Luen Wu et al. PLoS One
- Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo
- (2013) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
- (2013) M. Merchant et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool
- (2013) Y. Xu et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
- (2013) J. A. Couch et al. Science Translational Medicine
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12
- (2013) Yunji Wu et al. Cell Reports
- Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor
- (2013) Seung Y. Chu et al. Arthritis & Rheumatology
- Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer
- (2013) L. P. Richman et al. Cancer Immunology Research
- Nebulized Anti–IL-13 Monoclonal Antibody Fab′ Fragment Reduces Allergen-Induced Asthma
- (2012) Jonathan Hacha et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency
- (2012) M Chodorge et al. CELL DEATH AND DIFFERENTIATION
- Dornase alfa (Pulmozyme)
- (2012) Jeffrey S. Wagener et al. CURRENT OPINION IN PULMONARY MEDICINE
- Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody
- (2012) Seung Y. Chu et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
- (2012) Javier Chaparro-Riggers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Marketing approval of mogamulizumab
- (2012) Alain Beck et al. mAbs
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treating Diabetes and Obesity with an FGF21-Mimetic Antibody Activating the Klotho/FGFR1c Receptor Complex
- (2012) I. N. Foltz et al. Science Translational Medicine
- Pharmacological modulation of GITRL/GITR system: therapeutic perspectives
- (2011) Giuseppe Nocentini et al. BRITISH JOURNAL OF PHARMACOLOGY
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies
- (2011) Jennifer Q. Dong et al. CLINICAL PHARMACOKINETICS
- Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
- (2011) W. Wang et al. DRUG METABOLISM AND DISPOSITION
- Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development
- (2011) Nicholas W. Warne EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Modulation of antibody effector function
- (2011) John R. Desjarlais et al. EXPERIMENTAL CELL RESEARCH
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data
- (2011) Rong Deng et al. mAbs
- Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange
- (2011) Aming Zhang et al. PHARMACEUTICAL RESEARCH
- Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species
- (2011) Yulia Vugmeyster et al. PHARMACEUTICAL RESEARCH
- The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors
- (2011) Agnès Maillet et al. PHARMACEUTICAL RESEARCH
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
- (2010) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types
- (2010) Paula J. Kaplan-Lefko et al. CANCER BIOLOGY & THERAPY
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
- (2010) P. Lakatos et al. CURRENT DRUG TARGETS
- Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse
- (2010) Q.-H. Zhou et al. DRUG METABOLISM AND DISPOSITION
- Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
- (2010) Takuo Suzuki et al. JOURNAL OF IMMUNOLOGY
- Potential aggregation prone regions in biotherapeutics
- (2010) Xiaoling Wang et al. mAbs
- Single-Batch Production of Recombinant Human Polyclonal Antibodies
- (2010) Lars S. Nielsen et al. MOLECULAR BIOTECHNOLOGY
- Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood−Brain Barrier in the Mouse
- (2010) Qing-Hui Zhou et al. MOLECULAR PHARMACEUTICS
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reduced elimination of IgG antibodies by engineering the variable region
- (2010) T. Igawa et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- (2009) Y. A. Yeung et al. JOURNAL OF IMMUNOLOGY
- A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
- (2009) M. M. Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
- (2009) K Vandenbroucke et al. Mucosal Immunology
- Engineering of stable bispecific antibodies targeting IL-17A and IL-23
- (2009) Robert Mabry et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started